Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2005
03/17/2005WO2005023832A1 Compound and method for enhancing the cholesterol lowering property of plant sterol and stanol esters
03/17/2005WO2005023830A2 Ozonation products of cholesterol for the treatment and prevention of atherosclerosis and/or cardiovascular diseases
03/17/2005WO2005023826A2 Polymorphic nucleoside compounds
03/17/2005WO2005023819A1 Thienopyrroles as antiviral agents
03/17/2005WO2005023818A2 Heterobicyclic compounds as pharmaceutically active agents
03/17/2005WO2005023807A2 4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists
03/17/2005WO2005023806A2 Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands
03/17/2005WO2005023804A1 Peptidyl heterocyclic ketone derivatives and preparation processes
03/17/2005WO2005023800A1 Halo substituted benzo`b! thiophenes with pi3k inhibitory activity as therapeutic agents
03/17/2005WO2005023799A1 Fused bicyclic carboxamide derivatives and methods of their use
03/17/2005WO2005023794A2 Compound libraries of 4-carboxamidopiperidine derivatives
03/17/2005WO2005023792A2 Macrocyclic compounds useful as pharmaceuticals
03/17/2005WO2005023788A1 Fki-1366 substances and process for producing the same
03/17/2005WO2005023782A1 Substituted fused pyrimidine-4(3h)-one compound
03/17/2005WO2005023781A1 Guanidine derivatives
03/17/2005WO2005023780A1 Selective synthesis of cf3-substituted pyrimidines
03/17/2005WO2005023778A2 Process for preparation of rosuvastatin calcium
03/17/2005WO2005023777A1 Ppar-activating compound and pharmaceutical composition containing same
03/17/2005WO2005023773A1 Process for the preparation of substituted aryl pyrazoles
03/17/2005WO2005023772A1 Malonamide derivatives blocking the activity of gama-secretase
03/17/2005WO2005023769A1 Process for the preparation of amlodipine salts
03/17/2005WO2005023768A1 An improved process for the preparation of pure nisoldipine
03/17/2005WO2005023767A2 Diastereomers of 4-aryloxy-3-hydroxypiperidines
03/17/2005WO2005023766A1 Salt of atorvastatin with metformin
03/17/2005WO2005023763A1 Process for the preparation of pure levetiracetam
03/17/2005WO2005023761A2 Cytokine inhibitors
03/17/2005WO2005023759A2 Heterocyclic inhibitors of mek and methods of use thereof
03/17/2005WO2005023368A1 Prophylaxis of and treatment for infections from the family chlamydiaceae using amino acids as leucine or methionine
03/17/2005WO2005023328A2 Methods for intradermal delivery of therapeutics agents
03/17/2005WO2005023316A1 A radioisotope-chitosan complex for treatment of prostate cancer
03/17/2005WO2005023310A2 Polyamine-metal chelator conjugates
03/17/2005WO2005023306A2 Combination of medicaments comprising lansoprazole and domperidone
03/17/2005WO2005023305A2 Modulating cell activity by using an agent that reduces the level of cholesterol within a cell
03/17/2005WO2005023304A2 Antimalarial compositions and manufacturing process thereof
03/17/2005WO2005023296A1 Treatment of rheumatic diseases
03/17/2005WO2005023289A1 Medicinal composition for treating chronic hepatitis c
03/17/2005WO2005023274A1 Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
03/17/2005WO2005023273A1 Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents
03/17/2005WO2005023272A1 Pharmaceutical compositions and methods for lowering blood pressure and pulse rate
03/17/2005WO2005023271A1 Physiologically active composition based on phosphatidylserine
03/17/2005WO2005023270A2 Compositions and methods for use of antiviral drugs in the treatment of retroviral diseases resistant to nucleoside reverse transcriptase inhibitors
03/17/2005WO2005023269A1 Medicament compositions comprising a heterocyclic compound and an anticholinergic
03/17/2005WO2005023268A1 Application assembly for medicaments that are to be applied to the skin and packaging that is used as an application assembly
03/17/2005WO2005023267A1 Cyclohexyl prostaglandin analogs as ep4-receptor agonists
03/17/2005WO2005023266A1 The combination of a serotonin reuptake inhibitor and amoxapine
03/17/2005WO2005023265A1 Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
03/17/2005WO2005023264A1 Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate
03/17/2005WO2005023263A1 Use of tigecycline, alone, or in combination with rifampin to treat osteomyelitis and/or septic arthritis
03/17/2005WO2005023262A1 Oral itraconazole composition which is not affected by ingested food and process for preparing same
03/17/2005WO2005023261A1 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
03/17/2005WO2005023260A1 1- (2-amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
03/17/2005WO2005023259A1 Itraconazole solution
03/17/2005WO2005023258A1 Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives
03/17/2005WO2005023256A1 Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
03/17/2005WO2005023255A2 Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process
03/17/2005WO2005023253A1 Use of pde4 inhibitors for the treatment of diabetes mellitus
03/17/2005WO2005023252A1 Method of increasing the extent of absorption of tizanidine by combined intake with food
03/17/2005WO2005023250A1 Use of telmisartan for the prevention of vascular headache
03/17/2005WO2005023249A1 Novel orally administered dosage form for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -ethyl proprionate and salts thereof
03/17/2005WO2005023246A1 Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
03/17/2005WO2005023245A1 Novel cycloalkyl’b! condensed indoles
03/17/2005WO2005023244A1 7-carboxymethyloxy-3', 4', 5-trimethoxy flavone monohydrate, the preparation method and uses thereof
03/17/2005WO2005023243A1 The combination of a serotonin reuptake inhibitor and loxapine
03/17/2005WO2005023241A1 The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
03/17/2005WO2005023240A2 Pharmaceutical combination preparation containing glycyrrhizine, zinc, and a compound comprising a thiol group or a group that is metabolized thereto
03/17/2005WO2005023239A1 Pharmaceutical composition comprising i.a. vitamin c, magnesium, green tea extract for retarding cardiovascular diseases
03/17/2005WO2005023238A1 Erg channel openers for the treatment of hyperexcitability-related neuronal diseases
03/17/2005WO2005023237A1 Erg channel openers for the treatment of cardiac arrhythmias
03/17/2005WO2005023236A1 Phenylephrine tannate, pyrilamine tannate, and dextromethorphan tannate salts in pharmaceutical compositions
03/17/2005WO2005023234A1 Molecules exhibiting anti-adipogenic activity on adipocyte human cells
03/17/2005WO2005023233A2 Antimicrobial compositions and methods
03/17/2005WO2005023232A2 Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders.
03/17/2005WO2005023231A1 Polypyrimidine tract binding protein promotes insulin secretory granule biogenesis
03/17/2005WO2005023227A2 Nicotine formulations and use thereof
03/17/2005WO2005023225A1 Cilostazol adsorbate
03/17/2005WO2005023222A1 Pharmaceutical composition with improved solubility and fluidity
03/17/2005WO2005023218A1 Emulsion of perfluororganic combination with a function of gastransport
03/17/2005WO2005023216A2 Melt-formulated, multi-particulate oral dosage form
03/17/2005WO2005023207A1 Method of decreasing sebum production
03/17/2005WO2005023204A2 Aromatic prodrugs of propofol, compositions and uses thereof
03/17/2005WO2005023196A2 Compounds and methods
03/17/2005WO2005023192A2 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
03/17/2005WO2005023190A2 Treatment for cd5+ b cell lymphoma
03/17/2005WO2005023189A2 Method of cox-2 selective inhibitor and nitric oxide-donating agent
03/17/2005WO2005023188A2 Compounds and methods
03/17/2005WO2005023187A2 Inhibitor of cardiac tachyarrhythmias
03/17/2005WO2005023185A2 Pharmaceutical compositions and method of using levodopa and carbidopa
03/17/2005WO2005023184A2 Antibiotic product, use and formulation thereof
03/17/2005WO2005023183A2 Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use
03/17/2005WO2005023182A2 Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
03/17/2005WO2005023179A2 Combination methods of treating cancer
03/17/2005WO2005023178A2 Acridone derivatives as anti-herpesvirus agents
03/17/2005WO2005023175A2 Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound
03/17/2005WO2005023083A2 Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
03/17/2005WO2005023020A1 Composition and method for facilitating bone healing
03/17/2005WO2005023003A1 Antimicrobial mixtures comprising iodopropynyl compounds and dimethyldithiocarbamate derivatives
03/17/2005WO2005012543A3 Quantitative method for detecting yessotoxins in fish products based on the activation caused by the toxin in cellular phosphodiesterase and therapeutic usefulness of said activation
03/17/2005WO2005011649A3 Methods of treating severe acute respiratory syndrome virus infections
03/17/2005WO2005009431B1 Methods for treating inflammation and inflammation-associated diseases with a statin and ether
03/17/2005WO2005009330A3 Method of obtaining inhibitors of type ii dehydroquinase enzyme and precursors thereof
1 ... 4749 4750 4751 4752 4753 4754 4755 4756 4757 4758 4759 4760 4761 4762 4763 4764 4765 4766 4767 4768 4769 ... 7860